Biosimilars – commercial best practices in the age of sustainability

whitePaper | July 12, 2023

The discovery of nitrosamine genotoxins in several pharmaceuticals has led to monitoring and re-evaluation of manufacturing practices for those products considered atrisk. This article provides an assessment of nitrosamine contamination specifically in biologics and contrasts the potential risks between these product types.

whitePaper | October 10, 2022

Biotechnology and pharmaceutical industries continue to experience increased pressure on financial performance due to several factors.

whitePaper | April 24, 2023

Implementation of a metabolite-based cell density<br /> estimation and evaluation of harvest strategies for<br /> Lentivirus production with HEK293T cells

whitePaper | July 30, 2021

Clinical trials are complex, lengthy, and resource-inefficient. The clinical research industry is responsible for the delivery of medical solutions to society by systematically evaluating their safety and efficacy in humans during so-called clinical trials. As exemplified by the COVID-19 pandemic, a steady and efficient influx of vaccines, therapeutics, and other innovative medical solutions is critical for meeting society’s current and future medical needs. Unfortunately, the industry faces several persistent issues that make clinical trial operations overly complex, lengthy, and resource-inefficient.

whitePaper | February 11, 2022

The biomanufacturing revolution is here. Recent advancements in the field of synthetic biology have enabled significant cost reductions in foundational bioengineering unit operations such as DNA synthesis and sequencing.

whitePaper | June 10, 2022

Healthcare is changing rapidly. Companies who provide products and services to hospitals and physicians will need to adjust their operations to change.